Shanghai Jiaolian Pharmaceutical

Shanghai Jiaolian Drug Development is a biotechnology company based in Shanghai, China, that specializes in the research and development of innovative antibody-drug conjugates (ADCs) and monoclonal antibodies. Founded to advance targeted therapies for oncology and autoimmune diseases, the company was acquired by Shanghai Pharmaceuticals Holding Co., Ltd. (SPH) in 2014 and now serves as a key R&D subsidiary within the SPH group. Its pipeline features several high-potential candidates, including B001, a humanized anti-CD20 antibody in Phase 3 trials for primary membranous nephropathy, and B003, an anti-HER2 ADC currently in Phase 2 for breast cancer. The company also develops therapies targeting CD30, ROR1, and PEAR1, utilizing its expertise in site-specific conjugation and protein engineering. By integrating its discovery capabilities with SPH's manufacturing and commercial infrastructure, Shanghai Jiaolian aims to deliver next-generation biopharmaceuticals to the Chinese and global markets.